Calidi Biotherapeutics Inc. (CLDI) stock took a significant hit on Wednesday, plummeting by 13.3% to 98 cents per share. The decline came after the company announced a registered direct offering of 2,050,000 shares of common stock at $1.00 per share to institutional investors. This move suggests a need for additional funding, which often leads to a dip in share prices as investors digest the news.
In addition to the direct offering, Calidi Biotherapeutics also revealed a concurrent private placement, which will involve the issuance of Series E and F warrants. These warrants grant investors the right to purchase up to 2,050,000 additional shares at $1.13 per share. The Series E warrants have a one-year term and are exercisable six months after issuance, while the Series F warrants have a five-year term.
The transactions are anticipated to close around October 24, with Ladenburg Thalmann & Co. serving as the exclusive placement agent. This direct offering and private placement are likely to have a significant impact on CLDI’s stock price in the near future.
How To Buy CLDI Stock
If you’re interested in investing in Calidi Biotherapeutics, there are a few ways to acquire CLDI stock:
*
Brokerage Platform:
The most common method is through an online brokerage platform. You can purchase individual shares or fractional shares, allowing you to invest even if you have a limited budget.*
Exchange Traded Funds (ETFs):
ETFs provide diversified exposure to specific sectors or industries. If you are interested in the healthcare sector, you can invest in an ETF that holds shares in Calidi Biotherapeutics and other companies in the same industry.*
401(k) Strategy:
Many retirement plans, such as 401(k)s, allow you to allocate your investments to specific sectors or funds. You can allocate a portion of your 401(k) to a fund that seeks to acquire shares in companies like Calidi Biotherapeutics.CLDI’s Recent Stock Performance
Calidi Biotherapeutics’ stock has experienced significant volatility over the past year. It has reached a 52-week high of $29.30 and a 52-week low of $0.96. This drastic fluctuation highlights the inherent risk involved in investing in biotech companies, which are often subject to rapid changes in market sentiment and regulatory approvals.
The recent drop in CLDI shares is likely a result of the company’s need for additional capital, as well as the broader market uncertainty affecting biotech stocks. While this news may cause short-term volatility, long-term investors will need to carefully assess the company’s future prospects and its potential to generate sustainable growth.